Imidazopyridazine
![]() | |
| Identifiers | |
|---|---|
3D model (JSmol) |
|
| ChEMBL |
|
| ChemSpider | |
| EC Number |
|
PubChem CID |
|
| UNII |
|
CompTox Dashboard (EPA) |
|
| |
| |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references | |
Imidazopyridazine is a heterocyclic compound containing fused imidazole and pyridazine rings.[1][2] The fusion of these two heterocyclic rings can yield three different isomers, namely imidazo[4,5-c]pyridazine and imidazo[4,5-d]pyridazine, both of which contain two nitrogen atoms in each ring. A third possible structure is imidazo[1,2-b]pyridazine, in which one nitrogen atom is shared between the imidazole and pyridazine rings (and hence contains one less nitrogen atom and therefore is non-isomeric).[1]
Ponatinib, a medication used to treat chronic myeloid leukemia, contains an imidazo[1,2-b]pyridazine substructure. Examples of experimental drugs containing this ring system include darigabat (an imidazo[4,5-c]pyridazine), as well as GBLD-345 and SRI-42127 (both imidazo[1,2-b]pyridazines).
References
- 1 2 Malik MS, Alshareef HF, Alfaidi KA, Ather H, Abduljaleel Z, Hussein EM, et al. (January 2024). "Exploring the untapped pharmacological potential of imidazopyridazines". RSC Advances. 14 (6): 3972–3984. Bibcode:2024RSCAd..14.3972M. doi:10.1039/d3ra07280k. PMC 10823362. PMID 38288152.
- ↑ Volpi G, Laurenti E, Rabezzana R (June 2024). "Imidazopyridine Family: Versatile and Promising Heterocyclic Skeletons for Different Applications". Molecules. 29 (11). Basel, Switzerland: 2668. doi:10.3390/molecules29112668. PMC 11173518. PMID 38893542.
